Hepion Pharma's 2025 10-K Reveals Zero Revenue, $8.28M Net Loss, Clinical Trial Wind-Down
Summary
Hepion Pharmaceuticals reported its 2025 annual financial results in its 10-K, revealing zero commercial product revenue, a net loss of $(8.28) million, and $(0.88) diluted EPS. Critically, the company also disclosed the wind-down of its ASCEND-NASH clinical trial in 2024 due to a funding shortfall, a major setback for a development-stage biotech. While the company is pivoting towards CE-marked diagnostics, as previously indicated by an 8-K filing on March 3rd, these comprehensive annual results underscore severe financial challenges. The lack of revenue and significant losses, coupled with the inability to fund a key clinical program, are highly material for this micro-cap company, raising substantial concerns about its long-term viability and ability to execute on its new strategy. Traders will be monitoring any progress on the diagnostic front and future financing efforts.
At the time of this announcement, HEPA was trading at $0.05 on OTC in the Life Sciences sector, with a market capitalization of approximately $522.9K. The 52-week trading range was $0.03 to $267.50. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.